Huntington's Disease Trial Progress
Skyhawk Therapeutics Reports Favorable 12-Month Results for SKY-0515 in Huntington's Disease Trial
Anonymous
Skyhawk Therapeutics released twelve-month results from its Phase 1/2 trial of SKY-0515 in Huntington's Disease on June 30, 2026, showing favorable trends across all four key disease measures. Most strikingly, not a single clinician or patient reported disease progression over the full year — every participant either held steady or improved, according to Skyhawk Therapeutics.
The drug, an oral pill, targets RNA splicing to reduce the production of the toxic mutant huntingtin protein that destroys brain cells in HD patients. The results were shared at the European Academy of Neurology and mark a potential turning point in a disease that has defeated nearly every drug attempt for decades, Owen Sound Sun Times reported.
All Four Disease Measures Trend in Right Direction
The trial tracked four subcomponents of the cUHDRS — the gold-standard composite scale used to measure HD decline. These are: Total Functional Capacity (TFC), which measures daily independence; Total Motor Score (TMS), which tracks movement problems like chorea; Symbol Digit Modalities Test (SDMT), which gauges cognitive speed; and Stroop Word Reading Test (SWRT), which measures brain processing. SKY-0515 participants showed favorable trends across all four, according to Fairview Post.
Normally, HD patients lose roughly half a point to a full point on the TFC scale each year. In this trial, 92% of participants held their baseline score and 8% actually gained a point. Motor scores improved by a mean of 2.4 points. Cognitive processing speed, measured by SDMT, showed a mean increase of 1.2 symbols — a result described as the first recorded cognitive uptick in a year-long HD trial.
Zero Patients Reported Worsening — A First for HD Trials
Skyhawk also released Clinician Global Impression (CGI) and Patient Global Impression (PGI) survey data. The CGI asks doctors to rate each patient's overall disease state. The PGI asks patients to report how they feel. At twelve months, 100% of clinicians rated their patients as either "Stable" or "Improved." Zero clinicians reported progression, according to Sault Star.
On the patient side, 100% reported no worsening of symptoms. Forty-two percent said they felt subjective improvement in daily tasks and mood. CEO Bill Haney said the results "validate our belief that oral small molecules can achieve what biologics and gene therapies have struggled with: consistent, CNS-wide distribution with a safety profile that allows for long-term stabilization."
An Oral Pill Challenges Painful Injection-Based Rivals
Most HD drug candidates require intrathecal injections — a needle directly into the spinal canal. SKY-0515 is a daily pill. Skyhawk developed it using its SKYSTAR platform, which designs small molecules to correct faulty RNA splicing. The goal is to lower production of the mutant huntingtin protein before it can damage neurons, Pincher Creek Echo reported.
High-profile injection-based drugs like Roche's tominersen failed in prior trials, often because the drug could not reach the entire brain evenly. An oral drug circulates through the bloodstream and may solve that distribution problem. If the stabilization data holds, analysts say SKY-0515 could be a multi-billion dollar asset that pressures gene therapy competitors.
Experts Urge Caution as Phase 3 Looms Ahead
Not everyone is ready to celebrate. Some neurologists warn that 12 months is too short a window for a slow-moving disease like HD. Dr. Michael Hayden of Prilenia Therapeutics noted that "Huntington's is a marathon" and called for 24- and 36-month data before drawing firm conclusions. Independent researchers have also asked Skyhawk to release raw data on secondary RNA splicing events to rule out unintended effects on other genes, according to Cold Lake Sun.
The Phase 1/2 trial enrolled 74 patients in early-to-manifest stages of HD. A much larger Phase 3 pivotal trial will be needed before any regulatory approval. Insiders suggest the FDA may grant SKY-0515 Breakthrough Therapy Designation based on the cUHDRS stabilization, which could speed that path. There are roughly 30,000 symptomatic HD patients in the US and more than 200,000 gene carriers at risk of developing the disease.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
10
Reach
10
A
AnonymousAuthor
